dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Martínez-Trufero, Javier |
dc.contributor.author | De Sande-González, Luis Miguel |
dc.contributor.author | Luna, Pablo |
dc.contributor.author | Álvarez, Rosa |
dc.contributor.author | Valverde Morales, Claudia Maria |
dc.contributor.author | Martin-Broto, Javier |
dc.contributor.author | Marquina, Gloria |
dc.date.accessioned | 2021-06-01T11:26:30Z |
dc.date.available | 2021-06-01T11:26:30Z |
dc.date.issued | 2021-02-14 |
dc.identifier.citation | Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, et al. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers. 2021 Feb 14;13(4):792. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/6001 |
dc.description | L-sarcoma; Growth modulation index; Sarcoma |
dc.description.abstract | The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;13(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tumors de parts toves |
dc.subject | Medicaments - Eficàcia |
dc.subject.mesh | Soft Tissue Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Effectiveness |
dc.title | A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers13040792 |
dc.subject.decs | neoplasias de los tejidos blandos |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | efectividad |
dc.relation.publishversion | https://doi.org/10.3390/cancers13040792 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Martínez-Trufero J] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Álvarez R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Valverde-Morales CM] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33672857 |
dc.identifier.wos | 000623337400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |